Non-small cell lung cancer lung cancer
Conditions
Interventions
1) Perform 1st [18F]F-AraG PET/CT scanning within 2 weeks before the initial administration of immune checkpoint inhibitors
2) Perform 2nd [18F]F-AraG PET/CT scanning between 2 weeks and 6 weeks after
Sponsors
Nakamoto Yuji
Nobashi W Tomomi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Confirmed non-small cell lung cancer by pathology. 2) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2. 3) Patients without history of immune checkpoint inhibitors approved in Japan, but clinically applicable and planned to be prescribed. 4) Patients who performed FDG-PET/CT
Exclusion criteria
Exclusion criteria: 1) Pregnant, possibly pregnant, or breastfeeding women. 2) Very poor physical condition. 3) Outstandingly difficult in communication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimation of effective period of immune checkpoint inhibitors using [18F]F-AraG PET/CT by calculating delta SUVmax of primary site before and after starting immune checkpont inhibitors in non-small cell lung cancer patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| # Correlation of SUVmax, SUVmean, and the value of SUVmean multiplied by volume of interest in the 1st [18F]F-AraG PET/CT scanning, and the expression rate of CD8, PD-1, and Treg cells in pathological specimens from the primary site and available lymph nodes. # Comparison of pretreatment [18F]FDG PET/CT vs [18F]F-AraG PET/CT in terms of correlation of SUVmax, SUVmean, and the value of SUVmean multiplied by volume of interest and the expression rate of CD8, PD-1, and Treg cells in pathological specimens from the primary site and available lymph nodes. | — |
Contacts
Public ContactTomomi Nobashi
Kyoto University Hospital
Outcome results
None listed